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Abstract 30 
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 2 
Aspirin is one of the most frequently used drugs worldwide and is generally considered effective 32 
for the secondary prevention of cardiovascular disease (CVD). In contrast, the role of aspirin in 33 
primary prevention of CVD is controversial. Early trials evaluating aspirin for primary 34 
prevention, conducted before the turn of the millennium, suggested possible reductions in MI 35 
and stroke, although not mortality, and an increased risk of bleeding. In an effort to balance the 36 
risks and benefits of aspirin, international guidelines on primary prevention of CVD have 37 
typically recommended aspirin only when there is a substantial 10-year risk of CV events. 38 
However, recent, large randomized clinical trials of aspirin for the primary prevention of CVD 39 
demonstrate little or no benefit and possible harm. In this narrative review, we reappraise the role 40 
of aspirin in primary prevention of CVD contextualizing data from historical and contemporary 41 
trials.  42 
  43 
 3 
Introduction 44 
Extracted from willow bark, salicylates were first used as an analgesic by the ancient Sumerians 45 
and Egyptians.1 Later civilizations found salicylates to be an effective treatment for pain, 46 
inflammation, and fever; however, their use was limited by gastric side effects. Under the 47 
instruction of Arthur Eichengrun, the German chemist Felix Hoffmann discovered that 48 
incorporation of an acetyl group to salicylic acid reduces its propensity for gastric irritation, 49 
resulting in the first production of acetylsalicylic acid, known more commonly as aspirin, in 50 
1897 (Figure).2  51 
 Almost a century later, in 1974, a randomized controlled trial showed a non-significant 52 
reduction in deaths amongst patients with a recent myocardial infarction (MI) who were assigned 53 
to aspirin 330mg/day.3 This launched a series of trials that resulted in widespread acceptance of 54 
aspirin for the secondary prevention of major adverse cardiovascular events (MACE).4–11 55 
Enthusiasm for aspirin led to further randomized controlled trials investigating whether aspirin 56 
might be effective for the primary prevention of cardiovascular disease (CVD).12–17 Several 57 
primary prevention trials, mostly conducted before the turn of the millennium, suggested 58 
reduction in MI and stroke, although not mortality16, and at a cost of increased bleeding 59 
events.12–15 These findings influenced guidelines, which recommended prescribing aspirin for 60 
primary CVD prevention in high-risk individuals.18–20 Aspirin is now one of the most widely 61 
used medications. In the U.S. alone, it is estimated that 35.8 million adults are taking aspirin for 62 
the primary prevention of CVD, often without consulting their physicians.23  63 
 Despite aspirin’s popularity, its use for the primary prevention of CVD is controversial. 64 
Indeed, the U.S. Food and Drug Administration (FDA) has never approved the labeling of 65 
aspirin for this purpose. The European Medicines Agency (EMA) have not addressed this 66 
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question. Furthermore, recent clinical trial data have placed the utility of aspirin for the primary 67 
prevention of CVD back under scrutiny due to their neutral results24,25 or evidence of harm.26 In 68 
this article, we summarize the mechanism of action, review historical and contemporary trials 69 
evaluating aspirin, and reflect on future directions for aspirin in the prevention of CVD. 70 
 71 
Search Strategy and Selection Criteria 72 
PubMed was used to identify relevant references using the search terms “aspirin”, and “primary 73 
prevention”. We also searched all of the references in recent systematic reviews and metanalyses 74 
on this topic.27–29 Only articles published in English between January 1970 and January 2019 75 
were included in this narrative review. 76 
 77 
Mechanism of Action 78 
Acetylsalicylic acid binds to and irreversibly inhibits cyclooxygenase (COX), which exists as 79 
two isoforms in humans: COX-1 and COX-2.30 COX-1 is involved in platelet aggregation 80 
through production of thromboxanes. COX-2 is involved in the upregulation of prostaglandins 81 
that have vasodilator and anti-aggregatory actions.31 Both isoenzymes are associated with 82 
protection of the gastric mucosa.32 In experimental settings, low dose aspirin (75 mg or 81 mg) 83 
inhibits COX-1 and disrupts the production of thromboxane A2
33 thereby reducing platelet 84 
aggregation and formation of thrombus.34 Higher aspirin doses inhibit COX-235 leading to 85 
reduced production of prostacyclin and prostaglandin-E, which is responsible for aspirin’s 86 
analgesic and antipyretic effects but may cause vasoconstriction, renal dysfunction, 87 
hyponatremia, and pro-aggregatory effects.36 For patients with cardiovascular disease, doses of 88 
aspirin as low as 75mg/day may suffice to block both systems for 24 hours or more. 89 
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Trials of Aspirin for Primary Prevention Before 2000 90 
Non-targeted populations  91 
The first primary prevention trials investigating the utility of aspirin in preventing MI enrolled 92 
physicians, as was not uncommon at the time (Table 1). The British Male Doctors Trial 93 
randomized 5,139 men aged <80 years, 10-15% of whom had a prior history of non-MI 94 
cardiovascular disease, to 300-500 mg aspirin/day or no aspirin (unblinded).13,17 After a six-year 95 
follow up, there were no differences in the incidence of or mortality from stroke, MI, or other 96 
CVD. Importantly, the rates of non-fatal and fatal MI were similar, with sudden death notably 97 
included in the fatal MI endpoint. 17  98 
 The US Physicians’ Health Study enrolled 22,071 healthy male physicians aged 40-84 99 
years and randomized them, double-blind, to aspirin 325 mg every other day or placebo.13 The 100 
trial was stopped for futility by the data monitoring committee during an interim analysis 101 
because only 88 of the expected 733 cardiovascular deaths had occurred within the first 4.8 years 102 
of follow-up and because of an observed reduction in non-fatal and fatal MI, a key secondary 103 
endpoint. In the final report with full follow-up for events, the investigators found a 44% 104 
reduction in the rate of non-fatal and fatal MI in those assigned to aspirin (255 vs 440 per 105 
100,000 per year; p<0.00001). There was no reduction in angina, stroke, cardiovascular death, or 106 
all-cause mortality. The ratio of fatal to non-fatal MI was dramatically different in the British and 107 
US trials (ratio of ~1.0 in British and ~0.1 in US trials). The aspirin group had higher rates of 108 
bleeding [relative risk (RR) 1.32; 95% CI 1.25-1.40; p<0.00001] and were more likely to require 109 
a blood transfusion (RR 1.71; 95% CI 1.09-2.69; p=0.02).13 The early termination of the US trial 110 
for a reduction in a secondary endpoint, differences in population risk, and differences in the 111 
definition or ascertainment of MI may account for the divergent results found in the two trials. 112 
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Targeted populations with cardiovascular co-morbidities  113 
Subsequent studies shifted the focus to lower doses of aspirin and higher-risk groups for CVD, 114 
such as patients with hypertension and diabetes mellitus (DM). The Primary Prevention Project 115 
randomized 4,495 men and women with one or more cardiovascular risk factors to 100 mg/day 116 
aspirin or no aspirin without blinding.14 The trial terminated early at the second interim analysis, 117 
again despite no difference in the pre-specified primary outcome, after a median follow-up of 4 118 
years demonstrated a 44% reduction in cardiovascular death (RR 0.56; 95% CI 0.31-0.99) and 119 
23% reduction in total cardiovascular events (RR 0.77; 95% CI 0.62-0.95) with aspirin. There 120 
was no significant treatment effect on all-cause mortality, and there was also an increased rate of 121 
severe bleeding in the aspirin group (1.1% vs 0.3%; p<0.0008). Similarly, the Thrombosis 122 
Prevention Trial (TPT) found that men at high-risk for MI who received aspirin had a 32% 123 
reduction in nonfatal MI (p=0.004) over a 6.8-year median follow up. This effect was largely 124 
driven by the combination of aspirin with warfarin.12 Aspirin alone did not significantly reduce 125 
the primary endpoint of fatal or nonfatal MI compared to placebo. There was also no change in 126 
cardiovascular or non-cardiovascular death.  127 
 In the Hypertension Optimal Treatment (HOT) Study,15 researchers found a 15% risk 128 
reduction in the primary endpoint of major cardiovascular events (RR 0.85; 95% CI 0.73-0.99; 129 
p=0.03) and a 36% reduction in patient hospitalized with MI (RR 0.64; 95% CI 0.49-0.85, 130 
p=0.002) at 3.8-year mean follow-up. However, there were more silent MI events on aspirin (73) 131 
than placebo (57), which would have rendered the trial neutral had they been included in the 132 
primary endpoint. Furthermore, the inclusion of a number of patients with prior MI, stroke, and 133 
other CVD may have confounded the results of this trial from a primary prevention perspective; 134 
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though the authors reported no major difference in the effect of aspirin between the secondary 135 
prevention group and the general study population.  136 
Influence of Sex 137 
The Women’s Health Study (WHS) randomized 39,876 women to 100 mg aspirin on alternate 138 
days versus placebo.16 The primary endpoint of the trial was not met. Although there was a 17% 139 
reduction in stroke (RR 0.83; 95% CI 0.69-0.99; p=0.04), there was no change in the rates of MI 140 
or cardiovascular death over a mean follow up of 10.1 years. While subgroup analyses from the 141 
early trials and early meta-analyses suggested different effects of aspirin on men and women,37,38 142 
the 2009 Anti-Thrombotic Trials Collaboration metanalysis of six primary prevention trials 143 
found no sex-stratified differences when correcting for multiple testing.39 144 
 145 
Trials of Aspirin for Primary Prevention 2000 to 2017 146 
Major advances in cardiovascular risk reduction have been implemented in the last 20 years, 147 
including marked reductions in tobacco smoking,40,41 widespread evidence-based prescribing of 148 
statin therapy42, and improved population control of blood pressure43. Thus, the turn of the 149 
millennium brought about a reappraisal of aspirin’s safety and efficacy for the primary 150 
prevention of CVD (Table 2). Furthermore, the publication of a universal definition of MI and 151 
advances in the utilization of cardiac biomarkers, including more sensitive measures like 152 
troponin,44,45 improved the consistency of determining endpoints such as MI. 153 
Patients with Diabetes Mellitus  154 
Several contemporary trials have focused on patients with DM. The Prevention of Progression of 155 
Arterial Disease and Diabetes (POPADAD) trial enrolled 1,276 patients aged 40 years with 156 
type 1 or type 2 DM and an ankle-brachial pressure index of 0.99 or less but no symptomatic 157 
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CVD, to receive aspirin 100 mg daily or placebo. Aspirin did not reduce the primary composite 158 
endpoint of cardiovascular death, non-fatal MI, stroke, or amputation for critical limb ischemia 159 
(RR 0.98; 95% CI 0.76-1.26) or the rate of non-fatal MI alone.46 Similarly, the Japanese Primary 160 
Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial, which enrolled patients 161 
with type 2 DM aged 30 to 85 years, found that aspirin at a dose of 81 mg or 100 mg daily did 162 
not significantly reduce a composite outcome of atherosclerotic events at 4.4 years follow-up 163 
(RR 0.80; 95% CI 0.58-1.10; p = 0.16).47  164 
Patients with Other Cardiovascular Co-morbidities  165 
The Aspirin for Asymptomatic Atherosclerosis Trial (AAA) enrolled 3,350 men and women 166 
aged 50 to 75 years with low ankle-brachial index and no history of CVD. The trial was neutral 167 
for its primary endpoint, a composite of fatal or nonfatal coronary events, stroke, or 168 
revascularization (RR 1.03; 95% CI 0.84-1.27) and for all-cause mortality (RR 0.95; 95% CI 169 
0.77-1.16) over a mean follow up of 8.2 years.48 The Japanese Primary Prevention Project (JPPP) 170 
randomized 14,464 subjects aged 60-85 with multiple cardiovascular risk factors to aspirin 100 171 
mg daily or not (unblinded). The study was stopped early for futility on its composite outcome of 172 
cardiovascular death, nonfatal stroke, and nonfatal myocardial infarction, although a reduction in 173 
non-fatal MI was observed (RR 0.53; 95% CI 0.31-0.91; p=0.02). An increase in extra-cranial 174 
hemorrhage requiring transfusion or hospitalization (RR 1.85; 95% CI 1.22-2.81; p=0.004) was 175 
also observed.49  176 
 177 
Trials of Aspirin for Primary Prevention in 2018 178 
The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial randomized 12,546 men 179 
(aged 55) and women (aged 60) with moderate CVD risk (defined as a 10-year risk of 180 
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coronary heart disease of 10-20%) to 100 mg aspirin versus placebo.24 The primary endpoint, a 181 
composite of cardiovascular death, MI, unstable angina, stroke, or transient ischemic attack, was 182 
neutral (RR 0.96; 95% CI 0.81–1.13; p=0.60) and there was no difference in non-fatal MI. 183 
Gastrointestinal bleeding was higher in the aspirin group (RR 2.11; 95% CI 1.36–3.28; 184 
p=0.0007), but the rates of intracranial hemorrhage were similar (0.13% vs 0.18%). The study 185 
population included patients with high blood pressure (63%), cigarette use (29%), and high LDL 186 
(44%). While the estimated risk of CVD in the study population calculated based on risk scores 187 
was 17.3%, the event rates of cardiovascular disease were much lower than expected (less than 188 
10% over 10 years). The lower than anticipated event rates perhaps reflects the benefits of 189 
contemporary CVD preventive therapies. 190 
 The ASCEND (A Study of Cardiovascular Events in Diabetes) trial randomized 15,480 191 
subjects to aspirin or placebo.25 The study had a population with higher BMI, greater proportion 192 
of men, though lower proportion of smokers compared with the previous studies of prophylactic 193 
aspirin in diabetes. A 12% reduction in non-fatal vascular events with aspirin (RR 0.88; 95% CI 194 
0.79-0.97; p=0.01) was observed, but at an increased risk of major bleeding (RR 1.29; 95% CI 195 
1.09-1.52; p=0.003). The incidence of fatal bleeding (0.2 % vs. 0.2%) and hemorrhagic stroke 196 
(0.3% vs. 0.3%) did not differ between groups. There was no reduction in hard endpoints such as 197 
vascular death. During the course of the trial, due to lower than expected event rates, the Steering 198 
Committee added transient ischemic events to the primary composite endpoint, extended the 199 
study duration, and expanded the sample size. The large sample size enabled the detection of the 200 
relatively small absolute risk reduction of 1.1% in the efficacy endpoint. However, this must be 201 
weighed against the increased absolute risk of major bleeding of 0.9% and the lack of effect on 202 
CV or all-cause mortality. 203 
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 The most recent and largest of the contemporary trials examined the utility of aspirin 204 
among older patients. The ASPREE (Aspirin in Reducing Events in the Elderly) trial randomized 205 
19,114 health patients aged 70 years or older (≥65 years of age for Blacks and Hispanics) to 206 
aspirin 100 mg daily or placebo.26 At a median follow-up of 4.7 years, there was no difference in 207 
CV events, including fatal and nonfatal MI and stroke between the two groups (RR 0.95; 95% CI 208 
0.83-1.08).26 However, an increased in the risk of intra- and extra-cranial hemorrhage (RR 1.38; 209 
95% CI 1.18-1.62; p<0.001) and all-cause mortality (RR 1.14; 95% CI 1.01-1.29) was 210 
reported.26,50 The trial also showed no reduction in the primary endpoint, a composite of 211 
dementia, death, or persistent physical disability,51 which may be more important to some 212 
patients than the cardiovascular endpoints assessed, though is notably a heterogenous endpoint 213 
less likely to have been influenced by aspirin therapy.  214 
Certain limitations of the 2018 trials can contribute to their null results. First, in all 3 of 215 
the 2018 aspirin trials, compliance with random assignment to aspirin was relatively poor, at 60-216 
70%, resulting in significant cross-overs that might have influenced the null results. Second, the 217 
populations studied had lower than anticipated cardiovascular risk, which leaves unanswered the 218 
question of whether aspirin has benefit in higher risk populations. Third, only a small proportion 219 
of patients were treated with proton pump inhibitors, an intervention which may have improved 220 
rates of gastrointestinal bleeding in the aspirin arm. Fourth, there was a lack of information 221 
regarding the use of NSAIDs and alcohol which may increase bleeding risk. Fifth, the median 222 
follow-up time ranged 4.7-7.4 years which may be too short to appreciate primary preventative 223 
effects in cardiovascular disease. Finally, the 2018 trials did not provide information on modern 224 
risk stratification modalities such as coronary calcium score. 225 
Contemporary meta-analyses  226 
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A recent meta-analysis of 11 primary prevention aspirin trials with 157,248 individuals, reported 227 
in early 2019, found no reduction in all-cause mortality overall or amongst patients with diabetes 228 
or high CV risk.27 There was, however, an increase in the absolute risk of major bleeding by 229 
0.6% and intracranial hemorrhage by 0.1%.27 The aggregate analysis of all trials found a 230 
reduction in MI with aspirin use (RR=0.82, 95% CI 0.71–0.94, p=0.006). However, this 231 
reduction was no longer significant when only the more contemporary trials reporting after the 232 
year 2000 were included (RR=0.90, 95% CI 0.79–1.02, p=0.10).  233 
Another recent metanalysis included 13 trials with 164,225 participants.28 Aspirin 234 
reduced the composite outcome of cardiovascular mortality, nonfatal myocardial infarction, and 235 
nonfatal stroke (RR=0.89, 95% CI 0.84-0.95) with an absolute risk reduction of 0.38% (number 236 
needed to treat 265). There was no difference in all-cause or CV mortality. There was an 237 
increased rate of major bleeding events (RR=1.43, 95% CI 1.30-1.56) with an absolute risk 238 
increase of 0.47% (number needed to harm 210). Again, this analysis showed less benefit in 239 
more recent trials, including no significant effect on MI, although a modest reduction persisted in 240 
the composite cardiovascular outcome (RR=0.90, 95% CI 0.83-0.98).  241 
 242 
Can the Discordance between Older and Newer Aspirin Trials be Harmonized? 243 
While some might reasonably argue that aspirin has never been conclusively shown to be 244 
efficacious in primary CVD prevention, most would agree that any potential benefits of aspirin 245 
for this indication (specifically reductions in non-fatal CVD) are much less evident in 246 
contemporary trials than before. How can this apparent change in effect of aspirin on reducing 247 
non-fatal MI and stroke in primary prevention be explained? One of the leading hypotheses is 248 
that improved control of CVD risk factors, including smoking, hypertension and hyperlipidemia, 249 
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has rendered aspirin for primary prevention obsolete.52 This is certainly possible; aspirin is not 250 
known directly to inhibit atherogenesis or stabilize plaque nor does it specifically target any 251 
primordial risk factor for CVD. Rather, the presumed benefit of aspirin for primary prevention is 252 
to abort an impending or subclinical MI from becoming a manifest clinical MI by inhibiting 253 
platelet coagulation. Indeed, there is some evidence that most MIs are small and subclinical and 254 
that spontaneous lysis of a forming clot regularly aborts these before clinical manifestations 255 
occur, even without aspirin.53,54 However, if less of these subclinical MIs are happening because 256 
of improved control of causal risk factors for atherosclerosis (e.g., tobacco, inflammation, 257 
hypertension, hyperlipidemia, dysglycemia), then the role of aspirin will become less relevant 258 
and, eventually, perhaps even obsolete for primary prevention. 259 
The hypothesis that improved control of underlying CVD risk factors explains aspirin’s 260 
diminishing benefit in primary prevention can be examined. Based on our review of the major 261 
trials to date (Tables 1 and 2), we compared risk factor burden and prevalence of preventive 262 
treatments among participants of trials before and after 2000 (Table 3). It is important to note 263 
that contemporary trials sought to select study populations with high cardiovascular risk, such as 264 
patients with DM (e.g., POPADAD, JPAD, ASCEND) or multiple cardiovascular risk factors 265 
(ARRIVE). Ultimately, ARRIVE trial had lower than expected event rates of cardiovascular 266 
disease (less than 10% over 10 years) and therefore it may not capture aspirin’s effect on a 267 
higher risk population. Similarly, the ASCEND trial had a small percentage of patients (17%) 268 
with high estimated cardiovascular risk. 269 
To understand whether contemporary care may have impacted on the discordant results 270 
between historical and recent trials, we compared the cardiovascular risk factors present in the 271 
study populations of these trials. The weighted-average of mean systolic blood pressure (140 272 
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mmHg vs 157 mmHg), tobacco use rate (13.9% vs 15.6%), and mean total cholesterol [5.0 273 
mmol/L (193 mg/dl) vs 6.1 mmol/L (235mg/dl)] were all lower in trials reported after the year 274 
2000 but there was more obesity (body mass index 27.7 vs 26.9) and higher rates of DM (38.4% 275 
vs 4.4%) even when trials on diabetic patients were excluded (14% vs 4.4%). Statin use was 276 
generally not reported in the early aspirin prevention trials and was presumably very low. The 277 
first FDA approval of a statin therapy was not until 1987 and landmark randomized trials 278 
reporting the utility of statins in primary cardiovascular prevention did not report until the late 279 
1990s and 2000s.55,56 With the available data, however, it does appear statin use was markedly 280 
higher in the later aspirin primary prevention trials (47% vs 16%). It is possible that the greater 281 
use of statin therapy, and improvements in blood pressure control and smoking cessation, in 282 
more recent trials may have reduced the risk of plaque rupture events thus limiting the 283 
opportunity for aspirin to prevent major clinical events. 284 
Another potential explanation is that revisions of the definition of MI and the use of more 285 
sensitive cardiac biomarkers have reduced the reported benefit of aspirin in contemporary trials. 286 
The endpoint of non-fatal MI, in particular, is worth examining closely, as this is the endpoint 287 
that was most consistently improved in earlier aspirin trials (Table 4). The early trials utilized 288 
World Health Organization definitions of MI from the 1970s57,58 which explicitly did not include 289 
a standardized type or level of cardiac biomarker to categorize MI, as there was not enough data 290 
at the time to support endorsement of a particular laboratory test. As such, objective cardiac 291 
biomarker elevations were not required for the diagnosis of MI in many of the older trials.59 In 292 
the absence of cardiac-specific biomarkers, these early definitions of MI could be mimicked by 293 
pulmonary, gastrointestinal, or musculoskeletal disease which would confound the clinical 294 
endpoint assessed in the trials. Furthermore, the lack of sensitive biomarkers meant that larger 295 
 14 
MIs (such as those evident on ECG) were more likely to be detected than smaller MIs in these 296 
early trials. 297 
Newer MI definitions developed by the American Heart Association,60 American College 298 
of Cardiology,61 and European Society of Cardiology61,62 subsequently began to incorporate 299 
novel biomarkers more specific to cardiac damage such as CK-MB and troponin. The later 300 
aspirin trials adopted these contemporary definitions of MI. These differing criteria, and ability 301 
of recent trials to detect smaller MIs, might explain in part the discrepancy between older and 302 
more contemporary aspirin trials. One hypothesis is that the effect of aspirin on MI prevention 303 
may depend on how large the MI is. Potentially aspirin can prevent an evolving MI from 304 
becoming large enough to be diagnosed using older criteria, but may have less effect in 305 
preventing small plaque rupture events detectable by sensitive cardiac biomarkers.63 306 
This hypothesis (that aspirin might modify the presentation but not prevent MI) is 307 
consistent with the increased proportion of ‘silent’ MIs recorded in the aspirin arm of the HOT 308 
trial versus the placebo arm (48% vs 31% of all MIs were silent in the aspirin vs placebo arms).15 309 
This suggests that aspirin may be responsible for converting otherwise clinically manifest (or 310 
‘noisy’) MIs to silent ones. Because silent MIs appear to have similar prognostic implications to 311 
non-fatal MIs that are not silent,64,65 this might help to explain the consistent lack of benefit for 312 
aspirin on CVD death or all-cause mortality. More contemporary trials using highly sensitive 313 
cardiac biomarkers may also be subject to more ‘noise’ in the MI endpoint (e.g., some troponin 314 
elevations in more recent trials may reflect myocardial injury and not true type 1 MI), which 315 
could also explain the diminishing benefit for aspirin evident in trials using modern biomarkers. 316 
Despite the above arguments, any effective treatment for the prevention of MI should 317 
theoretically reduce downstream morbidity (e.g., heart failure) and death. While the lack of 318 
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benefit for fatal CVD in updated meta-analyses of primary prevention aspirin appears to confirm 319 
a diminishing effect of aspirin in recent trials, it is also true that case-fatality from MI has fallen 320 
in modern studies66,67 and that the relatively short follow-up of recent trials (typically <5 years 321 
on average) means that extended follow-up of these studies will be important to report. 322 
 323 
Current Guidelines 324 
Guidelines on the prophylactic use of aspirin to prevent CVD vary internationally but have 325 
become more conservative in recent years (Table 5). The 2016 European Society of Cardiology 326 
(ESC) primary prevention guideline recommends against initiating aspirin in individuals without 327 
overt cardiovascular disease.68 This was a downgrade from the 2007 ESC guideline which stated 328 
aspirin could be considered when the 10-year risk of cardiovascular mortality was substantial 329 
(SCORE risk>10%) and blood pressure was controlled.19 In contrast to current European 330 
recommendations, the 2016 United States Preventative Services Task Force (USPSTF) guideline 331 
recommends aspirin for patients aged 50-59 with a 10% or greater 10-year CVD risk and a low 332 
risk of bleeding (Grade B recommendation) but it is less enthusiastic for patients aged 60-69 and 333 
recommends an individualized decision regarding aspirin use.18 The 2015 American Heart 334 
Disease/American Diabetes Association (AHA/ADA) guidelines recommend low-dose aspirin 335 
for patients with diabetes who have a 10-year CVD risk of at least 10% but are not at increased 336 
risk of bleeding (Class IIa). They state low-dose aspirin is a reasonable choice for adults who 337 
have DM and a 10-year CVD risk between 5% and 10% (Class IIb).69 An updated joint AHA and 338 
American College of Cardiology guideline will be released in March 2019. 339 
 340 
Conclusion/Future Directions:  341 
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These new trials argue for a major change in how we prescribe aspirin for the prophylaxis of 342 
CVD. However, one caveat is that there remains a signal, albeit inconsistent, that aspirin might 343 
reduce non-fatal MI (e.g., this was evident in ASCEND and in the on-treatment analyses of 344 
ARRIVE). The prognosis of well-managed MI has improved greatly over the last 20 years66. 345 
Extended follow-up may now be required to determine whether possible reductions in non-fatal 346 
MI translate into a reduction in disability (heart failure) or death.  347 
 Modern approaches may help tailor treatment more precisely to an individual’s risks and 348 
benefit. Coronary artery calcium scores combined with risk calculators may enable personalized 349 
risk stratification and identification of primary prevention adults who are at sufficiently high risk 350 
for CVD to potentially benefit from aspirin.70,71 Risk scores need to be continually updated and 351 
validated to capture changes in demographics, smoking rates,40,41 pharmacologic management of 352 
cardiovascular risk,42 and obesity.72  353 
Methods to mitigate the risk of bleeding may influence the risk/benefit ratio of aspirin. 354 
Along these lines, there is some interest in weight-based aspirin dosing,73 though recent trials did 355 
not demonstrate effect modification by weight.74 Different formulations of aspirin and enteric 356 
coating may reduce gastro-intestinal toxicity,75 though this benefit must be weighed against 357 
potential reductions in antiplatelet effects with certain enteric-coated aspirin formulations.76 The 358 
concomitant use of proton pump inhibitors reduces gastrointestinal bleeding events.77,78 359 
Compared with proton pump inhibitors, assessment and treatment of helicobacter pylori offers a 360 
similar degree of protection from recurrent bleeding among aspirin users.79 Lifestyle 361 
modifications, such as minimizing NSAIDs and alcohol, might decrease gastrointestinal bleeding 362 
risk.80 Finally, the use of bleeding risk scores specific to aspirin can inform decisions 363 
surrounding aspirin prescribing.81 364 
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 The failure of recent trials of aspirin for primary prevention to demonstrate consistently a 365 
benefit for non-fatal and fatal CVD outcomes27,28 should also lead to reassessment of its role in 366 
secondary prevention, particularly in the post-acute setting (i.e., greater than 1 year post 367 
MI/stroke/revascularization).82 Indeed, intensive treatment of  CVD risk factors may also have 368 
diminished the benefit of aspirin for secondary prevention among persons with stable CVD, 369 
though for now guidelines continue to recommend life-long aspirin for secondary prevention.  A 370 
number of clinical trials have suggested that primary prevention aspirin might reduce the risk of 371 
developing cancer,83,84 though ASPREE unexpectedly showed an increase in cancer deaths with 372 
aspirin. Longer follow up from all the recent trials will be necessary to shed further light on this 373 
issue,85–87 and to guide aspirin prescription in specific patients with low hemorrhagic risk and 374 
high risk for both colon cancer and CVD.88 Regardless, aspirin’s cost-effectiveness for primary 375 
prevention was questionable even before the recent neutral trials.89,90 Lastly, in an era with a 376 
growing number of CVD therapies and increasing complexity of care, withdrawal of aspirin 377 
therapy in primary prevention should be considered where appropriate.   378 
In conclusion, aspirin does not reduce fatal cardiovascular events in patients who have 379 
not yet experienced a first event, but it does increase the risk of bleeding. However, case fatality 380 
from CVD has fallen dramatically in recent years so the potential importance of non-fatal 381 
endpoints must be borne in mind because aspirin still appears to reduce non-fatal MI, albeit less 382 
consistently and convincingly in contemporary trials. Thus, longer follow-up of recent pivotal 383 
trials will be important to see if aspirin might prevent heart failure and other morbid 384 
complications of MI over the longer term. Similarly, whether aspirin may have a role in 385 
preventing CVD in non-elderly adults who are higher risk than those studied in contemporary 386 
trials remains a dilemma and requires further study.  387 
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Table 1. Historic Randomized Control Trials for Aspirin in Primary Cardiovascular Prevention: Mid-enrollment Pre-2000. *fatal or nonfatal;  
BMI body mass index; CV cardiovascular; GI gastrointestinal; HLD hyperlipidemia; HTN hypertension; IHD ischemic heart disease; MI myocardial infarction; 
NR not reported; NS nonsignificant; PUD peptic ulcer disease; SBP systolic blood pressure 
 
  
Trial BMD PHS TPT HOT PPP WHS 
Year 1988 1989 1998 1998 2001 2005 
Enrollment Period 1978-1979 1981-1987 1984-1989 1992-1994 1994-1998 1992-1995 
Number of subjects 5139 22071 5085 18790 4495 39876 
Population 
Male physicians without history 
of MI, stroke, or PUD 
Male physicians ages 40-84 
without history of stroke, MI, 
cancer, or renal disease 
Men ages 45-69 at high risk for 
cardiovascular disease 
Men and women ages 50–80 
with hypertension 
Men and women ages  50 
with one or more 
cardiovascular risk factors 
Healthy women ages  45  
Control Arm no aspirin placebo placebo placebo no aspirin placebo 
Median Follow-up 5.5 years 5 years 6.8 years 3.8 years (mean) 4 years 10.1 years (mean) 
Mean Age 
47% age<60, 39% age 60-69, 
14% age 70-79 
41% age 40-49, 34% age 50-59, 
19% age 60-69, 7% age 70-84 
57 years 61 years 64 years 55 years 
Current smoking 30% 11% 41% 16% 15% 13% 
Hypertension Mean SBP 136, 18% HTN  4% HTN Mean SBP 139 Mean 170/105 Mean 145/85, 69% HTN 26% 
Hyperlipidemia NR 5% cholesterol  6.7 mmol/L Mean 6.4 mmol/L Mean 6.0 mmol/L Mean 6.2 mmol/l, 41% HLD 30% 
Statin use NR NR NR NR 16% NR 
Diabetes 2% 2% NR 8% 17% 3% 
Obesity NR 25% BMI26 Mean BMI 27.4 Mean BMI 28.4 Mean BMI 27.5, obesity 22% Mean BMI 26 
Females 0% 0% 0% 47% 57% 100% 
Dose of aspirin 300 or 500 mg 325 mg 75 mg 75 mg 100 mg 100 mg 
Primary 
endpoint 
CV Mortality (63.2 vs 62.3 per 
10,000 man-years, p=NS) 
CV Mortality (81 vs 83, RR 0.96, 
95% CI 0.6-1.54)  
IHD (154 vs 190 events, p=0.04) 
IHD excluding warfarin arm (83 
vs 107 events, p=NS)  
Major CV events (315 vs 368, 
RR 0.85, 95% CI 0.73-0.99, 
p=0.03) not including silent MI 
Major CV events (45 vs 64,  
RR 0.71, 95% CI 0.48-1.04) 
Major CV events (477 vs 522, 0.91, 
95% CI 0.80-1.03, p= 0.13) 
Secondary endpoint 
Nonfatal stroke (see below) and 
nonfatal MI (see below) 
MI (139 vs 239, RR 0.56, 95% 
CI 0.45-0.70, p<0.00001); 
Stroke (119 vs 98, RR 1.22,  
95% CI 0.93-1.60, p=0.15) 
Stroke (47 vs 48, 2.9 vs 3.0 per 
1000 man-years, p=NS) 
MI (82 vs 127 RR 0.64 95% CI 
0.49-0.85 p=0.002);  
Stroke (146 vs 148, RR 0.98, 
95% CI 0.78-1.24, p=0.88);  
CV mortality (133 vs 140, RR 
0.95, 95% CI 0.75-1.20, p=0.65) 
Total CV events (141 vs 187, 
RR 0.77, 95% CI 0.62-0.95); 
CV death (17 vs 31, RR 0.56, 
95% CI 0.31–0.99); all-cause 
mortality (see below) 
Fatal MI (14 vs 12, RR 1.16, 95% CI 
0.54-2.51, P = 0.70); Nonfatal MI (see 
below); Fatal stroke (23 vs 22, RR 
1.04, 95% CI 0.58-1.86 p=0.90) 
Nonfatal stroke (see below); CV death 
(120 vs 126, RR 0.95, 95% CI 0.74-
1.22; p= 0.68) 
Safety endpoint 
Extracranial bleeding  
(10.6 vs 7.4 per 10,000 man-
years, p=NS) 
Bleeding requiring transfusion  
(48 vs 28, RR 1.71, 95% CI 1.09 
-2.69, p=0.02) 
Major bleeding event (8 vs 4 
p=NS) Intermediate bleeding 
event (48 vs 33 p=NS) 
Fatal bleeds (7 vs 8, p=NS), 
Nonfatal major bleeds (129 vs 
70, RR 1.8, p<0.001)  
Severe bleeding (24 vs 6, 
p<0.0008) 
GI bleeding req transfusion (127 vs 91, 
RR 1.40, 95% CI 1.07-1.83, p=0.02) 
All-Cause Mortality 
143.4 vs 159.5 per 10,000 man-
years, p=NS 
205 vs 216, RR 0.95, CI 0.79-
1.15, p=0.60 
216 vs 205, 13.0 vs 12.2 per 
1000 man-years, p=NS 
284 vs 305, RR 0.93, 95% CI 
0.79-1.09, p=0.36 
62 vs 78, RR 0.81, 95% CI 
0.58-1.13 
609 vs 642, RR 0.95, 95% CI 0.85- 
1.06, p=0.32 
Nonfatal MI 
42.5 vs 43.3 per 10,000 man-
years, p=NS 
129 vs 213, RR 0.59, 95% CI 
0.47-0.74, p<0.00001 
94 vs 137, 5.8 vs 8.5 per 1000 
many-years, p=0.004 
82 vs 127, RR 0.64, 95% CI 
0.49-0.85, p=0.002*;  
157 vs 184, RR 0.85, 95% CI 
0.69-1.05, p=0.13*  
(including silent MI) 
15 vs 22, RR 0.69, 95% CI 
0.36-1.33 
184-181, RR 1.01, 95% CI 0.83-1.24, 
p=0.90 
Nonfatal Stroke 
32.4 vs 28.5 per 10,000 man-
years, p=NS 
110 vs 92, RR 1.20, 95% CI 0.91 
-1.59, p=0.20 
47 vs 48, 2.9 vs 3.0 per 1000 
man-years, p=NS*  
146 vs 148, RR 0.98, 95% CI 
0.78-1.24, p=0.88* 
15 vs 18, RR 0.84, 95% CI 
0.42-1.67 
198 vs 244, RR 0.81, 95% CI 0.67-
0.97, p=0.02 
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Table 2. Contemporary Randomized Control Trials for Aspirin in Primary Cardiovascular Prevention: Mid-enrollment Post-2000. *fatal or nonfatal; 
ABI ankle-brachial index; CV cardiovascular; DM Diabetes Mellitus; GI gastrointestinal; HLD hyperlipidemia; HTN hypertension; MI myocardial infarction; 
NR not reported; NS nonsignificant; SBP systolic blood pressure; TIA transient ischemic attack 
Trial POPADAD JPAD AAA JPPP ARRIVE ASCEND ASPREE 
Year 2008 2008 2010 2014 2018 2018 2018 
Enrollment Period 1997-2001 2002-2005 1998-2008 2005-2007 2007-2016 2005-2011 2010-2014 
Number of subjects 1276 2539 3350 14464 12546 15480 19114 
Population 
Men and women ages  
40 with DM and ABI ≤0.99 
Men and women ages 30-85 
with DM 
Men and women ages  
50-75 with ABI≤0.95 
Men and women ages 60- 
85 with HTN, HLD, or DM 
Men ages  55 with 2-4 CV 
risk factors; Women ages  
60 with  3 CV risk factors 
Men and women ages  
40 with DM 
Men and women ages  70 
Control Arm placebo no aspirin placebo no aspirin placebo placebo placebo 
Median Follow-up 6.7 years 4.4 years 8.2 years (mean) 5 years 5 years 7.4 years 4.7 years 
Mean Age 61 years 65 years 62 years 71 years 64 years 63 years 74 years (median) 
Current Smoking 31% 21% 33% 13% 29% 8% 4% 
Hypertension 
Mean 145/79 Mean 135/77 
58% HTN 
Mean 148/84 Mean 137/78, 
85% HTN 
Median SBP 145,  
63% HTN 
Mean SBP136,  
29% HTN,  
Mean 139/77, 
74% HTN 
Hyperlipidemia 
Mean 5.5 mmol/l Mean 5.2 mmol/l 
53% HLD 
Mean 6.2 mmol/l Mean 5.2 mmol/l 
72% HLD 
58% HLD Mean 4.2 mmol/l 
34% HLD 
Mean 5.2 mmol/l 
65% HLD 
Statin use NR 26% 4% increased to 25% NR 43% 75% 34% 
Diabetes 100% 100% 3% 34% 0% 100% 11% 
Obesity 
Mean BMI 29.3 Mean BMI 24 NR Mean BMI 24.2,  
36% BMI>25 
Mean BMI 28.4,  
79% BMI >25 
Mean BMI 31,  
85% BMI >25 
30% BMI>30 
Females 56% 44% 72% 58% 30% 27% 56% 
Dose of aspirin 100 mg 81 or 100 mg 100 mg 100 mg 100 mg 100 mg 100 mg 
Primary endpoint 
Major CV events (116 vs 
117, RR 0.98, 95% CI 0.76-
1.26, p=0.86); CV death (43 
vs 35, RR 1.23, 95% CI 0.79 
-1.93, p=0.36) 
Major CV events (68 vs 86, 
RR 0.80, 95% CI 0.58-1.10, 
p=0.16) 
Major CV events (13.7 vs 
13.3 per 1000 person-years, 
RR 1.03, 95% CI 0.84 
-1.27) 
Major CV events (193 vs 
207, RR 0.94, 95% CI 0.77 
-1.15, p=0.54) 
Major CV events (269 vs 281, 
RR 0.96, 95% CI 0.81–1.13, 
p=0.60) 
Major CV events (658  
vs 743, RR 0.88, 95%  
CI 0.79-0.97, p=0.01) 
Death, dementia, or 
persistent physical disability 
(21.5 vs 21.2 per 1000 
person-years, RR 1.01, 95% 
CI 0.92-1.11, p=0.79) 
Secondary endpoint 
All-cause mortality (see 
below); non-fatal myocardial 
infarction (see below); 
Other vascular events (not 
included) 
CV mortality (1 vs 10, RR 
0.10, 95% CI 0.01-0.79 
p=0.0037); CHD events (28 
vs 35, RR 0.81, 95% CI 0.49 
-1.33, p=0.40); nonfatal MI 
or stroke, all-cause mortality 
Composite of primary end 
point or angina, claudication, 
or TIA (22.8 vs 22.9 per 
1000 person-years, RR 1.00, 
95% CI, 0.85-1.17) and all-
cause mortality (see below) 
Composite of primary 
endpoint or atherosclerosis 
(280 vs 319, RR 0.89 95% 
CI 0.75-1.04 p=0.14), CV 
death (58 vs 57, RR 1.03, 
95% CI 0.71-1.48, p=0.89) 
Composite and individual 
outcomes of the time to CV 
death, MI, or stroke. Time to 
UA; time to TIA; and time to 
death (p=NS for all endpoints) 
Any major vascular 
event (833 vs 936, RR 
0.88, 95% CI 0.80-0.97); 
GI cancer (157 vs 158, 
RR 0.99, p=NS) 
Major CV events (10.7 
events vs 11.3 per 1000 
person-years, RR 0.95, 95% 
CI 0.83-1.08) 
Safety endpoint 
GI bleeding 
(28 vs 31, RR 0.90, 95% CI 
0.53-1.52, p=0.69) 
Hemorrhagic stroke or  
severe GI bleeding (10 vs 7 
p=NS) 
Major hemorrhage req 
hospitalization 
(34 vs 20, RR 1.71,  
95% CI 0.99-2.97) 
Extracranial bleed req 
transfusion or hospital (62 
vs 34, RR 1.85, 95% CI 
1.22-2.81, p=0.004) 
GI bleeding events (61 vs 29, 
RR 2.11, 95% CI 1.36–3.28, 
p=0.0007) 
Major bleeding event 
(314 vs 245, RR 1.29, 
95% CI, 1.09-1.52, 
P=0.003) 
Major hemorrhage (8.6 vs 
6.2 per 1000 person-years, 
RR 1.38, 95% CI 1.18-1.62, 
P<0.001) 
All-Cause Mortality 
94 vs 101, RR 0.93, 95% CI 
0.71-1.24, p=0.63 
34 vs 38, RR 0.90,  
95% CI 0.57-1.14, p=0.67 
176 vs 186, RR 0.95,  
95% CI 0.77-1.16 
297 vs 303, RR 0.99 95% 
CI, 0.85-1.17, p=0.93 
160 vs 161, RR 0.99, 95% CI 
0.80–1.24, p=0.95 
748 vs 792, RR 0.94, 
95% CI 0.85-1.04 
12.7 vs 11.1 per 1000 
person-years, RR 1.14, 95% 
CI 1.01 to 1.29 
Nonfatal MI 
55 vs 56, RR 0.98, 95% CI 
0.68-1.43, p=0.93 
12 vs 9, RR, 1.34 95% CI  
0.57-3.19, p=0.50 
62 vs 68 p=NS 20 vs 38, RR 0.53, 95% CI 
0.31-0.91, P = 0.02 
88 vs 98, RR 0.90, 95% CI 
0.67-1.20, p=0.46 
191 vs 195, RR 0.98, 
95% CI 0.80–1.19 
171 vs 184, RR 0.93, 95% 
CI 0.76-1.15* 
Nonfatal Stroke 
29 vs 41, RR 0.71, 95% CI 
0.44 to 1.14, p=0.15 
22 vs 24, RR 0.93, 95% CI 
0.52-1.66, p=0.80 
37 vs 38 p=NS 117 vs 114, RR 1.04, 95% 
CI 0.80-1.34, p=0.78 
75 vs 67, RR 1.12, 95% CI 
0.8-1.55, p=0.51* 
202 vs 229, RR 0.88, 
95% CI 0.73-1.06 
148 vs 167, RR 0.89, 95% 
CI 0.71-1.11* 
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Table 3. Cardiovascular Risk Burden and Statin Use in Historic and Contemporary Trials 
 
 
Pre-2000 weighted 
average 
Trials included 
Post-2000 weighted 
average 
Trials included 
Smoking (%) 15.6 BMD, PHS, TPT, HOT, PPP, WHS 13.9 POPADAD, JPAD, AAA, JPPP, ARRIVE, ASCEND, ASPREE 
HTN (average SBP) 157 BMD, TPT, HOT, PPP 140 POPADAD, JPAD, AAA, JPPP, ARRIVE, ASCEND, ASPREE 
DM (%) 4.4 BMD, PHS, HOT, PPP, WHS 38.4 POPADAD, JPAD, AAA, JPPP, ARRIVE, ASCEND, ASPREE 
Obesity (average BMI) 26.9 TPT, HOT, PPP, WHS 27.7 POPADAD, JPAD, JPPP, ARRIVE, ASCEND 
Cholesterol (average mmol/L) 6.1 TPT, HOT, PPP 5.0 POPADAD, JPAD, AAA, JPPP, ASCEND, ASPREE 
Statin use (%) 16 PPP 47 JPAD, AAA, ARRIVE, ASCEND, ASPREE 
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Table 4. Definitions of Nonfatal Myocardial Infarction: *Cardiac enzymes during this time were SGOT, CK, LDH 
 
Trial Definition of Nonfatal Myocardial Infarction  
BMD 
Self-reported myocardial infarctions which were confirmed by cardiologist or neurologist review and classified as “definite”, “probable”, or “doubtful” event, with “doubtful” events 
removed from the analysis 
PHS World Health Organization criteria (1971) 
 1) ECG with unequivocal changes or 
 2) Atypical or typical symptoms with equivocal ECG and elevated enzymes* or 
 3) Typical history and elevated enzymes* with ECG negative or not available 
TPT  World Health Organization criteria (1976) 
HOT At least 2 of 3 
1. Central chest pain lasting for more than 15 min 
2. Transient elevation of enzymes* indicating myocardial damage 
3. Typical ECG changes 
PPP At least 2 of 3 
1. Chest pain of typical intensity and duration 
2. Transient increase of serum enzymes* concentration indicating myocardial damage 
3. Typical ECG changes  
WHS Symptoms met World Health Organization criteria and if the event was associated with abnormal levels of cardiac enzymes* or diagnostic ECG 
POPADAD Definition according to the World Health Organization criteria 
JPAD Not reported  
AAA American Heart Association Criteria (Gillum 1984) 
1. Evolving diagnostic ECG and/or 
2. Diagnostic ECG and abnormal enzymes (CK, CKMB, SGOT, LDH) and/or  
3. Prolonged cardiac pain and abnormal enzymes (CK, CKMB, SGOT, LDH) 
JPPP European Society of Cardiology and American College of Cardiology Criteria (Luepker 2003) 
1. Evolving diagnostic ECG, or 
2. Diagnostic biomarkers (CK, CK-MB, CK-Mbm, or cTn) 
ARRIVE At least 2 of 3 
1. A consistent clinical history 
2. ECG consistent with ischemia  
3. Cardiac biomarkers elevation  
ASCEND Evidence of cardiac necrosis (cardiac biomarkers) and evidence of acute MI (symptoms, new ECG changes, imaging or angiography) 
ASPREE European Society of Cardiology and the American College of Cardiology Criteria (Alpert 2000) 
1) Rise and fall of biomarkers (CK-MB or troponin) with at least one of the following:  
a) Ischemic symptoms 
b) Development of pathologic Q waves on the ECG 
c) ECG changes indicative of ischemia (ST segment elevation or depression)  
d) coronary artery intervention 
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Table 5. Summary of Major International Guidelines on Aspirin in Primary Cardiovascular Prevention  
 
 
  
Year Guideline Recommendation  
2002 USPSTF  Consider use of aspirin with adults at risk for coronary heart disease (5-year risk over 3%) 
2002 AHA  Consider use of aspirin with adults 10% or more 10-year risk of cardiovascular disease 
2007 ESC Consider use of aspirin when the 10-year risk of cardiovascular mortality is significantly increased (SCORE risk>10%) and blood pressure is controlled 
2009 USPSTF Recommend aspirin for men ages 45 to 79, and women ages 55 to 79 when cardiovascular benefit outweighs the risk of bleed (Grade A) 
2015 AHA/ADA Recommend aspirin for DM patients who have a 10-year CVD risk of at least 10% but are not at increased risk of bleeding (Class IIa). Aspirin is reasonable for adults 
who have DM and a 10-year CVD risk between 5% and 10% (Class IIb) 
2016 USPSTF Recommend aspirin in patients aged 50-59 with a 10% or greater 10-year CVD risk and low risk of bleeding (Grade B) 
2016 ESC Recommend against initiating aspirin in individuals without overt cardiovascular disease 
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Figure Legend: 
Figure illustrating the history of aspirin for use in the primary prevention of cardiovascular disease including major completed trials, FDA reviews, and international practice 
guidelines.  
 
